AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation coefficients and ICC between self-reported and device-based measures
Number of subjects: 2524
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman plots
Number of subjects: 2524
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 2524
Study 33502773 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (all types)
Number of subjects: 5929
Study 33502773 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulants
Number of subjects: 5929
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrelapse radiation therapy among previously nonirradiated SJYC07 patients
Number of subjects: 127
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation for SJMB03 patients
Number of subjects: 127
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 tumors
Number of subjects: 127
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-matched tumor pairs
Number of subjects: 127
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup and subtype stability
Number of subjects: 127
Study 33502920 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare subgroup divergence
Number of subjects: 127
Study 33503046 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 polymorphism genotyping
Number of subjects: 239
Study 33503046 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PPI doses or use of PPIs not metabolized by CYP2C19 (rabeprazole)
Number of subjects: 239
Study 33503342 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (52-mg)
Number of subjects: 711
Study 33503342 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD (T380A)
Number of subjects: 711
Study 33503481 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiview latent analysis method, group factor analysis
Number of subjects: 476
Study 33503481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of positive and negative valence
Number of subjects: 476
Study 33503568 — intervention group
Group type: EXPERIMENTAL
Intervention: sEH-derived fatty acid diols in depressed participants
Number of subjects: 40
Study 33503568 — intervention group
Group type: EXPERIMENTAL
Intervention: 12(13)-EpOME and 10(11)-EpDPE in depressed participants
Number of subjects: 40
Study 33503568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of 12,13-DiHOME/12(13)-EpOME in depressed participants
Number of subjects: 40
Study 33504077 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS) to invite individuals for HCV testing
Number of subjects: 51
Study 33504077 — intervention group
Group type: COMPARATOR
Intervention: Reference group methodology for outreach
Number of subjects: 51
Study 33504514 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-based risk assessment tool
Number of subjects: 2007
Study 33504514 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG predictors (heart rate, QTc-interval, rhythm, atrioventricular block, ST-segment depression, bundle branch block, ventricular extrasystole/non-sustained ventricular tachycardia)
Number of subjects: 2007
Study 33504920 — intervention group
Group type: EXPERIMENTAL
Intervention: Large diameter scleral lenses
Number of subjects: 13
Study 33505178 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote autorefraction with pupillary diameter and age as target, using a donated spectacle with a 'B' grade similarity.
Number of subjects: 10
Study 33505178 — intervention group
Group type: COMPARATOR
Intervention: Best corrected acuity at 20/20.
Number of subjects: 10
Study 33505222 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured ankles (acute intra-articular fractures)
Number of subjects: 55
Study 33505222 — intervention group
Group type: COMPARATOR
Intervention: Healthy contralateral ankles
Number of subjects: 55
Study 33505222 — intervention group
Group type: COMPARATOR
Intervention: Serum cytokine levels
Number of subjects: 55
Study 33505321 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 Polyunsaturated Fatty Acids supplementation
Number of subjects: 0
Study 33505321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33505715 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autografting augmented with topical application of MMC (0.2 mg/mL)
Number of subjects: 63
Study 33505715 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autografting augmented with Ologen implantation
Number of subjects: 63
Study 33505726 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l/min supplemental oxygen during bronchoscopy
Number of subjects: 92
Study 33505726 — intervention group
Group type: COMPARATOR
Intervention: No oxygen administration during bronchoscopy
Number of subjects: 92
Study 33505995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0
Study 33505995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33506139 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited access SAVR via J-shaped upper hemi-sternotomy (UHS)
Number of subjects: 80
Study 33506139 — intervention group
Group type: COMPARATOR
Intervention: Conventional SAVR through full median sternotomy (FMS)
Number of subjects: 80
Study 33506177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab combined with laser (G2)
Number of subjects: 32
Study 33506177 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment (G1)
Number of subjects: 32
Study 33506571 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg twice daily
Number of subjects: 45
Study 33506635 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (75 mg once daily, adjusted to maintain Hb target of ≥10.0 to <12.0 g/dL)
Number of subjects: 25
Study 33506635 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (dose-titrated for 24 weeks)
Number of subjects: 25
Study 33506766 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted methylation analysis of circulating cell-free DNA (cfDNA)
Number of subjects: 6689
Study 33506990 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic risk score developed using clinical, laboratory, and imaging data
Number of subjects: 600
Study 33506990 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable models using nine independent predictors of mortality
Number of subjects: 600
Study 33507158 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-Step e-intervention (5 sessions, guided by trained nonspecialist 'e-helpers')
Number of subjects: 1136
Study 33507158 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 1136
Study 33507454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavorixafor 400 mg daily plus nivolumab 240 mg every 2 weeks
Number of subjects: 9
Study 33507479 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 674
Study 33507479 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing capacity
Number of subjects: 674
Study 33507479 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness knowledge
Number of subjects: 674
Study 33507479 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge
Number of subjects: 674
Study 33507604 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and topotecan (VT) neoadjuvant intravenous chemotherapy
Number of subjects: 27
Study 33507803 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T-cell product targeting multiple tumor-associated antigens (TAAs) including PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1, administered at a fixed dose of 0.5 × 10^6 T cells, with a maximum tested dose of two infusions of 2 × 10^6 T cells
Number of subjects: 32
Study 33507822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirdametinib (PD-0325901) at 2 mg/m, administered by mouth twice a day
Number of subjects: 19
Study 33507832 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention skills assessed by parent questionnaire (Child Behavior CheckList) and performance-based assessment (Conner's Continuous Performance Test-Second Edition)
Number of subjects: 150
Study 33507832 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized reading comprehension test (ORLEC Lobrot)
Number of subjects: 150
Study 33507832 — intervention group
Group type: COMPARATOR
Intervention: NF1 group
Number of subjects: 150
Study 33507832 — intervention group
Group type: COMPARATOR
Intervention: Non-NF1 group
Number of subjects: 150
Study 33508469 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-High CRP
Number of subjects: 132
Study 33508469 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD (combined group)
Number of subjects: 132
Study 33508469 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 132
Study 33508475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Duke criteria without transesophageal echocardiography
Number of subjects: 261
Study 33508475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Duke criteria with transesophageal echocardiography
Number of subjects: 261
Study 33508475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography alone
Number of subjects: 261
Study 33508475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Duke criteria, heart murmur, and intensive care therapy
Number of subjects: 261
Study 33508475 — intervention group
Group type: COMPARATOR
Intervention: Patients with IE
Number of subjects: 261
Study 33509098 — intervention group
Group type: EXPERIMENTAL
Intervention: i-ACT system
Number of subjects: 48
Study 33509135 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), 10 sessions as part of normal clinical management.
Number of subjects: 64
Study 33509135 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention).
Number of subjects: 64
Study 33509155 — intervention group
Group type: EXPERIMENTAL
Intervention: FitSpirit PA intervention (motivational talks, turnkey running program, PA sessions, special events)
Number of subjects: 0
Study 33509155 — intervention group
Group type: EXPERIMENTAL
Intervention: FitSpirit PA intervention
Number of subjects: 0
Study 33509156 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 0
Study 33509215 — intervention group
Group type: EXPERIMENTAL
Intervention: EMiC2 continuous veno-venous haemodialysis (CVVHD)
Number of subjects: 12
Study 33509259 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN-ASD
Number of subjects: 61
Study 33509259 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN no-ASD
Number of subjects: 61
Study 33509259 — intervention group
Group type: EXPERIMENTAL
Intervention: macro-ASD
Number of subjects: 61
Study 33509259 — intervention group
Group type: COMPARATOR
Intervention: PTEN mutation groups
Number of subjects: 61
Study 33509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Data strengthening (DS) and modified WHO Safe Childbirth Checklist (mSCC)
Number of subjects: 0
Study 33509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training and mentoring (PRONTO)
Number of subjects: 0
Study 33509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) Collaborative
Number of subjects: 0
Study 33509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall integrated package of interventions
Number of subjects: 0
Study 33509390 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 34
Study 33509403 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0
Study 33509403 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging classification
Number of subjects: 0
Study 33509647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with chemotherapy
Number of subjects: 5
Study 33509647 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 + chemotherapy
Number of subjects: 5
Study 33509647 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 + chemotherapy
Number of subjects: 5
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy performed within 24 hours
Number of subjects: 1198
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1198
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 1198
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient management
Number of subjects: 1198
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of mortality
Number of subjects: 1198
Study 33509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite or presumptive source of bleeding disclosed
Number of subjects: 1198
Study 33509972 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-806
Number of subjects: 0
Study 33510343 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized eHealth-based management service (CS)
Number of subjects: 2195
Study 33510343 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 2195
Study 33510610 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy for ET
Number of subjects: 8
Study 33510610 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS pallidotomy for PD
Number of subjects: 8
Study 33510610 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofocusing echo imaging technique
Number of subjects: 8
Study 33510610 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS lesioning
Number of subjects: 8
Study 33510705 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33511161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Number of subjects: 0
Study 33511161 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 33511299 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)
Number of subjects: 0
Study 33511479 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR-group (kidney-transplanted recipients)
Number of subjects: 120
Study 33511479 — intervention group
Group type: COMPARATOR
Intervention: C-group (control group)
Number of subjects: 120
Study 33511479 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR-group
Number of subjects: 120
Study 33511479 — intervention group
Group type: COMPARATOR
Intervention: C-group
Number of subjects: 120
Study 33511576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 33511576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33511633 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation for primary pulmonary rehabilitation
Number of subjects: 1904
Study 33511633 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation for primary rehabilitation compared to no rehabilitation
Number of subjects: 1904
Study 33511633 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation for maintenance rehabilitation compared to no rehabilitation
Number of subjects: 1904
Study 33512057 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day ECG patch monitor
Number of subjects: 35
Study 33512323 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided online therapy (1 session per week for 6 weeks, utilizing cognitive behavioral therapy and acceptance and commitment therapy)
Number of subjects: 60
Study 33512323 — intervention group
Group type: COMPARATOR
Intervention: Self-help internet-based therapy (automatic weekly newsletter with self-help information and tips)
Number of subjects: 60
Study 33512323 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided online therapy
Number of subjects: 60
Study 33512323 — intervention group
Group type: COMPARATOR
Intervention: Self-help internet-based therapy
Number of subjects: 60
Study 33512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored PA internet intervention arm
Number of subjects: 43
Study 33512327 — intervention group
Group type: COMPARATOR
Intervention: Nutrition and wellness internet control arm
Number of subjects: 43
Study 33512414 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR22 therapy (1 × 10^6 CAR+ T cells per kilogram targeting CD22)
Number of subjects: 3
Study 33512414 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR22 therapy
Number of subjects: 3
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrates or cryoprecipitates as prophylaxis (35% of patients, n=72)
Number of subjects: 204
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥1 injection per week (18.1% of patients, n=37)
Number of subjects: 204
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment (16.6% of patients, n=34)
Number of subjects: 204
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous thrombotic event (37 patients, 18.1%)
Number of subjects: 204
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and residence in Asia or Africa
Number of subjects: 204
Study 33512441 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic events reported
Number of subjects: 204
Study 33512452 — intervention group
Group type: EXPERIMENTAL
Intervention: VLS-101 (antibody-drug conjugate targeting ROR1)
Number of subjects: 4
Study 33512452 — intervention group
Group type: EXPERIMENTAL
Intervention: VLS-101
Number of subjects: 4
Study 33512666 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 90 or 180 mg every 12 weeks for at least 48 weeks
Number of subjects: 110
Study 33512717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 1125
Study 33512741 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxman scalp cooling (SC) device
Number of subjects: 15
Study 33512794 — intervention group
Group type: EXPERIMENTAL
Intervention: MOWOOT device (intermittent colonic exo-peristalsis) used daily for 20 minutes over 4 weeks
Number of subjects: 92
Study 33512804 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome IV criteria
Number of subjects: 600
Study 33512804 — intervention group
Group type: COMPARATOR
Intervention: Rome III criteria
Number of subjects: 600
Study 33512804 — intervention group
Group type: COMPARATOR
Intervention: Potential Asia criteria
Number of subjects: 600
Study 33512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow Stimulation (MS)
Number of subjects: 0
Study 33512974 — intervention group
Group type: COMPARATOR
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 0
Study 33512974 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral Allograft (OCA) Transplantation
Number of subjects: 0
Study 33512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid-based Scaffold
Number of subjects: 0
Study 33512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Atelocollagen-based Gel
Number of subjects: 0
Study 33512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized Allogeneic Cartilage Scaffold
Number of subjects: 0
Study 33512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic Hydrogel (PEG diacrylate and denatured fibrinogen)
Number of subjects: 0
Study 33513026 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant 400 mg orally once daily
Number of subjects: 57
Study 33513030 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab/lenalidomide/dexamethasone (D-Rd)
Number of subjects: 0
Study 33513030 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 33513030 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab/bortezomib/dexamethasone (D-Vd)
Number of subjects: 0
Study 33513030 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 0
Study 33513187 — intervention group
Group type: EXPERIMENTAL
Intervention: Navina Smart (electronic transanal irrigation system)
Number of subjects: 89
Study 33513294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1096
Study 33513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33513372 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRix-RICE (rituximab 375 mg/m2) plus autologous HSCT
Number of subjects: 79
Study 33513372 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRix-RICE plus autologous HSCT
Number of subjects: 79
Study 33513373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Number of subjects: 949
Study 33513373 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 949
Study 33513373 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 949
Study 33513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0
Study 33513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone supplementation
Number of subjects: 0
Study 33513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 0
Study 33513712 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaomi Domestic Wristbands for sleep tracking
Number of subjects: 0
Study 33513935 — intervention group
Group type: EXPERIMENTAL
Intervention: TILT-123
Number of subjects: 0
Study 33513935 — intervention group
Group type: EXPERIMENTAL
Intervention: TILT-123 + anti-PD-1
Number of subjects: 0
Study 33514428 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (EMBARK)
Number of subjects: 239
Study 33514428 — intervention group
Group type: COMPARATOR
Intervention: Control (DESIR)
Number of subjects: 239
Study 33514524 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3321367 (TIM-3 mAb)
Number of subjects: 0
Study 33514524 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3321367 with LY300054 (anti-PD-L1 antibody)
Number of subjects: 0
Study 33514524 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33515034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake
Number of subjects: 1249
Study 33515034 — intervention group
Group type: COMPARATOR
Intervention: Niacin, vitamin B-12, or folate intake
Number of subjects: 1249